Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Autor: Ryan, Charles J., Smith, Matthew R., de Bono, Johann S., Molina, Arturo, Logothetis, Christopher J., de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, Josep M., Ng, Siobhan, Carles, Joan, Mulders, Peter F.A., Basch, Ethan, Small, Eric J., Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D., Suttmann, Henrik, Gerritsen, Winald R., Flaig, Thomas W., George, Daniel J., Yu, Evan Y., Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S., Taplin, Mary-Ellen, Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I., Rathkopf, Dana E., COU-AA-302 Investigators, [missing], Rottey, Sylvie

Publikováno v: Ryan, C J, Smith, M R, de Bono, J S, Molina, A, Logothetis, C J, de Souza, P, Fizazi, K, Mainwaring, P, Piulats, J M, Ng, S, Carles, J, Mulders, P F A, Basch, E, Small, E J, Saad, F, Schrijvers, D, van Poppel, H, Mukherjee, S D, Suttmann, H, Gerritsen, W R, Flaig, T W, George, D J, Yu, E Y, Efstathiou, E, Pantuck, A, Winquist, E, Higano, C S, Taplin, M E, Park, Y, Kheoh, T, Griffin, T, Scher, H I & Rathkopf, D E 2013, ' Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy ', New England Journal of Medicine, vol. 368, no. 2, pp. 138-148 . https://doi.org/10.1056/NEJMoa1209096
The New England Journal of Medicine, 368, 2, pp. 138-48
New England Journal of Medicine, 368(2), 138-148. Massachussetts Medical Society
The New England journal of medicine, vol 368, iss 2
New England journal of medicine, 368(2), 138-148. Massachussetts Medical Society
The New England Journal of Medicine, 368, 138-48
NEW ENGLAND JOURNAL OF MEDICINE

Contains fulltext : 118780.pdf (Publisher’s version ) (Closed access) BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbe01fb64ce8478aeb4e1b0bc046cfc
https://doi.org/10.1056/nejmoa1209096

New Therapeutics to Treat Castrate-Resistant Prostate Cancer

Autor: Ömer Acar, Tarık Esen, Nathan A. Lack

Publikováno v: The Scientific World Journal, Vol 2013 (2013)
The Scientific World Journal

The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9933c8fd76ae593fc0825cd3b33553f6
https://doaj.org/article/89e1bc989e6049a2b5c09a8e07ca45f3

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.